Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United States.

Conclusions: Tildrakizumab is among the most cost-effective first-line therapies for moderate-to-severe plaque psoriasis and is more cost-effective than secukinumab, ixekizumab, guselkumab, adalimumab, ustekinumab, and etanercept.
PMID: 32602762 [PubMed - as supplied by publisher]

Source: Journal of Dermatological Treatment - July 2, 2020 Category: Dermatology Tags: J Dermatolog Treat Source Type: research